CTIS2022-500777-14-00进行中（未招募）1 期
A phase 2b, randomised, double-blind, placebo-controlled, multi-site, parallel-group, dose finding trial to evaluate the efficacy and safety of different doses of subcutaneously administered LEO 138559 in adult subjects with moderate-to-severe atopic dermatitis (AD) - LP0145-2240
eo Pharma A/S0 个研究点目标入组 250 人开始时间: 2023年6月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •18-75 years old (both included) at screening (Visit 1)., At screening, diagnosis of - AD as defined by the Hanifin and Rajka (1980) criteria for AD. History of AD for =1 year., Subjects who have a recent history (within 12 months before screening) with documented inadequate response to treatment with TCS (±TCI as appropriate) or for whom these topical AD treatments are medically inadvisable (e.g. due to important side effects or safety risks)., EASI score =12 at screening and =16 at baseline., vIGA-AD score =3 at screening and baseline., BSA of AD involvement =10% at screening and baseline., ADSD Worst Itch score (weekly average) =4 at baseline.
排除标准
- •History of clinically significant infection within 4 weeks prior to baseline which, in the opinion of the investigator, may compromise the safety of the subject in the trial, interfere with evaluation of the IMP, or reduce the subject’s ability to participate in the trial. Clinically significant infections are defined as: - a systemic infection. - a serious skin infection requiring parenteral (IV or intramuscular) antibiotics, antiviral, or antifungal medication., Receipt of blood products within 28 days prior to screening., Treatment with: - Any marketed or investigational biologic agents within 3 months or 5 half-lives, whichever is longer, prior to baseline. - Any cell-depleting agents including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer., Treatment with TCS, TCI, topical PDE-4 inhibitors, topical JAK inhibitors, or other medicated topical treatments within 7 days prior to baseline, Receipt of live attenuated vaccines 30 days prior to baseline., Non-serious skin infection within 7 days prior to baseline., Presence of hepatitis B or C infection at screening., History of HIV infection or positive HIV serology at screening., Evidence of active or latent tuberculosis according to local standard of care for patients requiring initiation of a biologic treatment., Women who are pregnant or breastfeeding., Previous exposure to fezakinumab (anti-IL-22 Ab)., Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), immunomodulating drugs, retinoids (e.g. alitretinoin), corticosteroids (steroid eyedrops and inhaled or intranasal steroids are allowed), or JAK inhibitors within 28 days or 5 half-lives prior to baseline, whichever is longer., Use of tanning beds or phototherapy (NBUVB, UVB, UVA1, PUVA), within 4 weeks prior to baseline.
研究者
相似试验
进行中（未招募）
不适用
A phase 2b, randomised, double-blind, placebo-controlled, multi-centre, dose-finding study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of BG9924 when given in combination with methotrexate to subjects with active Rheumatoid Arthritis who have had an inadequate response to anti-TNF therapyRheumatoid arthritis (RA)MedDRA version: 9.1Level: PTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-005467-26-BEBiogen Idec Ltd120
进行中（未招募）
不适用
A phase 2B, randomised, double-blind, placebo-controlled, parallel group,multi-centre study to investigate the efficacy, mechanism of action,pharmacokinetics, safety and tolerability of the mGluR5 negativeallosteric modulator ADX10059 as monotherapy in patients withGastroesophageal Reflux Disease (GERD)Gastroesophageal Reflux DiseaseMedDRA version: 9.1Level: LLTClassification code 10018203Term: GERDEUCTR2008-005104-10-ATAddex Pharma SA100
进行中（未招募）
不适用
A phase 2B, randomised, double-blind, placebo-controlled, parallel group, dose-ranging, multicentre study to investigate the efficacy, safety and tolerability of the mGluR5 negative allosteric modulator ADX10059 for the prevention of migraineMigraineEUCTR2008-005481-30-ATAddex Pharma SA300
进行中（未招募）
不适用
A phase 2B, randomised, double-blind, placebo-controlled, parallel group,multi-centre study to investigate the efficacy, mechanism of action,pharmacokinetics, safety and tolerability of the mGluR5 negativeallosteric modulator ADX10059 as monotherapy in patients withGastroesophageal Reflux Disease (GERD)EUCTR2008-005104-10-BEAddex Pharma SA100
进行中（未招募）
1 期
A phase 2B, randomised, double-blind, placebo-controlled, parallel group,multi-centre study to investigate the efficacy, mechanism of action,pharmacokinetics, safety and tolerability of the mGluR5 negativeallosteric modulator ADX10059 as monotherapy in patients withGastroesophageal Reflux Disease (GERD)Gastroesophageal Reflux DiseaseMedDRA version: 9.1Level: LLTClassification code 10018203Term: GERDEUCTR2008-005104-10-FRAddex Pharma SA100